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ABSTRACT 
BACKGROUND 
Nigeria which has one of the world's 
highest burden of children living with 
Sickle cell anaemia is also endemic for 
hepatitis B, C and the Human 
immunodeficiency virus (HIV). This study 
set out to determine the prevalence of 
Hepatitis B surface antigen (HBsAg), 
antibodies to Hepatitis C Virus (HCV) and 
Human Immunodeficiency Virus (HIV) 
among children with Sickle cell anaemia 
(SCA) at the University of Port Harcourt 
Teaching Hospital (UPTH). 
METHODS 
This was a prospective hospital based 
study of children with sickle cell anaemia 
aged 0.5 years to 18years presenting at the 
haematology clinic of UPTH. A 
serological screening was carried out 
over a period of five months to determine 
the presence of hepatitis B virus (HBV), 
HCV and HIV 1 and 2 infection. Other 
data obtained included sex, age and 
other demographic data. 
RESULTS 
There were 182 SCA patients with 72 
(54.5%) males and 60 (45.5%) females. 
Results of HCV anti-body, HBSAg, and 
HIV were available for 84 patients. Mean 
age was 7.45 ± 1.6 years, age range was 
0.5-18years Seventy-eight (59.1%) had no 
previous blood transfusion, forty (80.8%) 
had one previous transfusion while eight 
(6.1%) had more than one previous 
transfusions. HBsAg was positive in three 
patients giving a prevalence of 8.6%; 
Anti-HCV antibody was not found in any 
patient while two (2.4%) were positive for 
HIV 1. There was no patient with 
Hepatitis, HIV and SCA. 
CONCLUSION 
This study showed no co-infection with 
Hepatitis B, C and HIV viral infection 
among children with SCA at UPTH, 
Nigeria. 
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INTRODUCTION 
Sickle cell anaemia (SCA) is an inherited form 
of haemolytic anemia and one of the most 
common in our society.1 It is a major cause of 
morbidity and mortality in Nigeria with a 
prevalence rate of 3%.1 .It is an autosomal 
recessively inherited disorder resulting in a 
chronic and frequently life-threatening 
anaemia that often requires red cell 
transfusion in its management. 2 
Individuals living with SCA are known to 
experience complications such as iron 
overload, red cell alloimmunization and 
transmission of infections such as malaria, 
hepatitis B (HBsag), hepatitis C (HCV) and 
Human Immunodeficiency Virus (HIV). 3 
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Co-infection with HIV and Hepatitis viruses 
are severe and frequent in sub-Saharan Africa 
especially in adults. 4-7 • However, in a 
systematic review, theco-infection with all 
three viruses was only been reported in one 
Nigerian child.8 The prevalences of HIV/HBV 
in children from Tanzania and Cote d'I voire 
have been reported as 1.2%9 and 12.1%10 
respectively, while the prevalence ofHIV/HBV 
co-infection among Nigerian children was 
8.3%8 • The rate of HIV/HCV co-infection in 
Tanzanian children was 13.8%9 • No child was 
found to be co-infected with HCV in an Ivorian 
study10• A HIV/HCV co-infection rate of 2.7% 
was reported among some Nigerian children in 
astudy8 • 
Common medical interventions for SCA 
patients in Nigeria include blood transfusion 
and injections, scarifications, tattooing and 
ritual marks by herbalists. These 
interventions predisposes them to risk of 
infection with transfusion transmissible 
viruses as suggested by the report of some 
studies2'11 which document an increased risk 
of transfusion transmissible viral infection in 
patients with SCA 2'11 • 
The transmission of Hepatitis B has been 
documented to be more common than that of 
Hepatitis C as a shown by the result of some 
studies12-1\ which documented a risk of HCV 
transmission through needle stick injury is in 
the order of 1-3%, compared with 30% for 
hepatitis B virus and 0.3% for HIV12-14• 
Though Hepatitis B, C and HIV share similar 
mode of transmission through sexual 
intercourse, mother-to-child, and blood 
transfusion15-1\ the risk of transmission and 
virulence of these viruses is known to be 
different. 
Patients with SCA are subjected to recurrent 
blood transfusion as part of their 
management. In spite of the progress made in 
the prevention of transfusion-transmitted 
infections over the last years, the risk of 
transfusion transmitted infection is still likely 
to occur especially in multi-transfused 
patients such as sickle cell anemia (SCA) 
patients18'19• 
Though HIV co-infections with HBV and HCV 
have been documented in children8 , there is a 
paucity of data on this subject among children 
with SCA especially in Nigeria despite their 
substantial risks for infection. This descriptive 
study was therefore designed to estimate the 
prevalence of co-infections with HIV, hepatitis 
B and C viruses in Nigerian children with SCA 
presenting to the Paediatrichaematology 
clinic ofUPTH . 
MATERIALS AND METHOD 
A case control study of 132 children with sickle 
cell anaemia aged 0.5 to 18 years presenting at 
the Haematology Clinic of the University of 
Port Harcourt Teaching Hospital over a five 
month period was done. The following 
information: age, gender, haemoglobin 
genotype and anti-HCV anti-body titre, serum 
HBsAg level, HIV 1 and 2 status were obtained 
from the subjects. The control groupwere 101 
paediatric patients in the same age bracket 
who were transfused in the paediatric wards of 
UPTH for various reasons other than SCA. All 
the patients were screened prior to blood 
transfusion. Serum samples were collected 
from 132 consecutive known SCA patients, 
presenting to Haematology Clinic of the 
department of Paediatrics, UPTH. Some of 
the mothers of those who were positive were 
also screened. A second-generation rapid 
screening test, the HEP C SPOT HCV assay 
was used for HCV. Initial reactive results were 
confirmed by repeat testing with UBI HCV 
EIA 4.0 enzyme immunoassay. The samples 
were screened for HBsAg by latex 
agglutination technique. All positive samples 
were tested using Enzyme linked Immuno-
sorbent Assay (ELISA) technique (pathogyme 
Omega Diagnostics, UK) for confirmation, 
while HIV status was screened for by ELISA. 
Analysis was done using the statistical 
package for social sciences version 20, p-value 
< 0.05 was considered statistically significant. 
Ethical clearance was obtained from the 
University of Port Harcourt Teaching 
Hospital, (UPTH), research and ethics 
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committee. Patient confidentiality was given Table 2: Sex Distribution and HIV Status of84 children 
the utmost priority in the course of the study. with Sickle Cell Anaemia 
Age (years) Anti-HCV status 
RESULTS 
The subjects comprised 132 sickle cell 
anaemia patients 72(54.5%) males and 
60(45.5%) females. The mean age of the 
patients was 7.45± 4.6years (range 0.5-18 
years) Seventy-eight( 59.1 %) had no previous 
transfusion, forty (30.3%)had one previous 
transfusion while eight (6.1%) had more than 
one previous transfusions Results of HCV 
anti-body, HBsAg, and HIV was available for 
84patients 44(52.4%) males and 40(47.6%) 
females Hepatitis B surface antigen markers 
was found in the sera of three patients ( 1male 
and two females) giving a prevalence of 3.6%, 
Anti-HCV antibody was not found in any 
patient giving a prevalence of 0% , while two 
(2.4%) were positive for HIV 1. There was no 
SCA patients with HIV, HBV and anti HCV: 
neither was there any Coinfection of HIV and 
HBV or HIV and HCV in any of the subjects 
with sickle cell anaemia. 
Of the two SCA patients who were HIV 
positive, one(1.2%) was via blood transfusion 
while the second one (1.2%) was via vertical 
transmission. The three subjects who were 
HBSag positive all had previous history of 
blood transfusion. 
In the control samples of 101 subjects. 
Serologic reactivity for antibody to HCV was 
found in four ( 4% ),HBSag one ( 1%) and HIV 1 
forty-three (42.5%). There was also no 
Coinfection of all three viruses (HIV, HBSag 
and anti HCV antibody) nor was there any 
coinfection ofHIV/HCVor HIV/HBSag in the 
control samples. 
The sex distribution of the subjects and HIV, 
HCV anti-body and HBSag status is as shown 
in Tables 1, 2 and 3. 
Table 1: Sex Distribution and Anti-HCV Status of 84 


























Table 3: Sex Distribution and HBSag Status of 84 
















The prevalence ofHBsAg in children with SCA 
in our study which has been reported earlier is 
3.6%22. This is slightly lower when compared 
with a previous study23from our Centre which 
showed a prevalence of 4.9%. The observed 
difference may result from the fact that 
uneven risk groups were used in the two 
studies. While this study was done on subjects 
with sickle cell disease the other done was 
among all blood donors. The prevalence of 
HbSAg, HCV and HIV co-infection reported in 
this study is however; lower than that of 
previous Nigerian studies24. 25which showed 
HBV carrier rates of8-22%. 
The prevalence of HCV anti-body in children 
with SCAin Port Harcourt is 0% This is within 
the range of 0-1.5% reported in South 
Africa28, but lower than the prevalence rate 
of 5.3% and 6.6% reported among non-
transfused and transfused SCA patients in 
Enugu, Nigeria11. The difference in the rates 
noted between the study in Enugu and this 
study may be influenced by the overall 
prevalence ofHCV in both areas, the quality of 
blood screening, the number of transfusions 
which increased the risk and the impact of 
scarification which was a significant predictor 
in the Enugu study11. The serological 
screening for anti-HCV at blood banks after 
1992 has contributed to a better control of the 
dissemination of HCV infection. This might 
also account for the 0% prevalence rate for 
antibody to HCV observed in this study as 
blood is routinely screened for antibody to 
HCV in University of Port Harcourt teaching 
Hospital. 
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The prevalence of HIV was 2.4% among SCA 
patients in this study. It is low when compared 
to the national AIDS prevalence of3.1% in the 
population21. One of the mothers of the two 
SCA patients who were sero-positive for HIV 
in this study was negative while the second 
mother was positive.This implies that one of 
the children was probably infected through 
vertical transmission from his mother while 
the second may have been infected via blood 
transfusion as an infant. 
In Zaria a prevalence of HIV of 1.8% 27 was 
observed among SCA patients, however the 
population studied was younger than those in 
this study and the sample size was also 
smaller, these factors may have accounted for 
the variation. A 0% prevalence was found in 
Senegal among patients with sickle cell 
anaemia28 which is lower than that gotten in 
this study though the blood transfusion rate in 
the Senegal study was 41%28 while the blood 
transfusion rate in this study was 30%. In the 
developed nations of the world the risk of 
transfusion-transmissible viral infection is 
primarily due to failure of serologic screening 
tests to detect recently infected blood donors in 
the pre-seroconversion "window" phase of 
infection.29 In order to reduce this "window" 
period nucleic acid testing (NAT) techniques 
are beginning to find applications in developed 
countries.29 The NAT techniques are complex, 
labourious, and presently time-consuming 
tests, and may take a while before getting to 
third world countries where HIV infection is 
prevalent. As a result serologic testing will 
remam the mainstay of screening blood 
donors. 
There was a 0% prevalence of Coinfection of 
HCV antibody, HBSag and HIV among 
patients with sickle cell anaemia in Port 
Harcourt Nigeria.The control group also 
showed a prevalence of 0% Coinfection of all 
three viruses. 
This is similar to other studies on co-infection 
in Nigeria 8,30, 31 and Cote d Ivoire10. It is 
however lower than the prevalence rate of 
coinfection of 0.04% to 7.2%found in 
Cameroon, keffi. and Ibadan among adults .. 
The fact that the study population were adult 
non SCA may have accounted for this 
difference. 
This study also recorded a 0% prevalence of 
HIV/HBSag coinfection rate in SCApatients 
and their control in Port Harcourt. This is 
lower than the prevalence rates of0.78% and 
31.4%, obtained from previous studies on co-
infection within and outside Nigeria5,8-
10,30,31 This shows that rate of co-infection 
varies from one locale to another across 
Africa. 
The rate ofHIV/HCV co-infection ofO% in this 
study is similar to an Ivorian and a Nigerian 
study10,30 but lower than varied HIV/HCV 
co-infection of rates 0.06% to 13.8% reported 
by other workers.5,7-9,31 This other studies 
were mostly among adult HIV patients and 
blood donors, which may have accounted for 
this difference. 
CONCLUSION 
No co-infection of HbSAg, HCV and HIV was 
reported among patients with SCA in Port 
Harcourt. The prevalence of solitary Hepatitis 
B and HIV infection reported in this study was 
also lower than the general prevalence in Port 
Harcourt and other areas of Nigeria. These 
findings indicate the need to promote optimal 
blood screening before transfusion as well as 
routing implementation of safe blood 
transfusion practice. Other management 
strategies which will reduce the risk and need 
of transfusion in SCA patients should be 
encouraged in order to reduce the co-morbidity 
associated with SCAin Nigeria. 
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